Docebo (DCBO) EBITDA Margin (2019 - 2026)

Docebo (DCBO) has reported EBITDA Margin for 8 consecutive years, with 3.76% the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, EBITDA Margin fell 306.0% year-over-year to 3.76%; the trailing twelve-month figure through Jun 2026 stood at 7.14% (down 84.0% YoY), and the FY2025 full-year result was 9.57%, down 24.0% from the prior year.
• EBITDA Margin improved to 3.76% in Q2 2026 per DCBO's latest filing, from 2.28% in the prior quarter.
• Across five years, EBITDA Margin topped out at 24.41% in Q3 2022 and bottomed at 21.43% in Q1 2022.
• Historically, EBITDA Margin has averaged 5.26% across 5 years, with a median of 6.75% in 2023.
• The sharpest annual moves came in 2022 and 2023: EBITDA Margin surged 3078 bps in 2022, then tumbled 2329 bps in 2023.
• Over 5 years, EBITDA Margin stood at 5.8% in 2022, then jumped by 127 bps to 13.19% in 2023, then increased by 4 bps to 13.72% in 2024, then climbed by 8 bps to 14.82% in 2025, then sank by 75 bps to 3.76% in 2026.
• According to Business Quant data, EBITDA Margin over the past three periods registered 3.76%, 2.28%, and 14.82% for Q2 2026, Q1 2026, and Q4 2025 respectively.